Open Access
Subscription Access
An Essential Parameters of Pneumococcal Vaccine Include Objectives, Mechanism of Action, Administration, Adverse Effects and Contraindications
Abstract
A major advancement in the treatment and prevention of a common and occasionally fatal disease process has been the development of pneumococcal vaccinations. The recommendations for pneumococcal conjugate vaccines vary based on the patient population. Both vaccination types have been shown to produce durable antibodies in individuals with weakened immune systems, but combination vaccines have also been shown to have some further advantages. This exercise describes the mechanism of action of pneumococcal vaccines, as well as delivery techniques, formulations, adverse event profiles, eligible patient demographics, and monitoring. It also emphasizes the importance of the interprofessional team in managing these patients.
References
Marijam A, Olbrecht J, Ozakay A, Eken V, Meszaros K. Cost-Effectiveness Comparison of Pneumococcal Conjugate Vaccines in Turkish Children. Value Health Reg Issues. 2019 Sep;19:34-44. [PubMed]
Huang J, Luo S, Huang M, Zhang T, Min Z, Liu C, Zhang Q, Yang J, Min X. Protection against fatal pneumonia through mucosal and subcutaneous immunization with the pneumococcal SP0148 protein. Microb Pathog. 2019 Apr;129:206-212. [PubMed]
Wiese AD, Griffin MR, Grijalva CG. Impact of pneumococcal conjugate vaccines on hospitalizations for pneumonia in the United States. Expert Rev Vaccines. 2019 Apr;18(4):327-341. [PMC free article] [PubMed]
Ozlu T, Bulbul Y, Aydin D, Tatar D, Kuyucu T, Erboy F, Koseoglu HI, Anar C, Sunnetcioglu A, Gulhan PY, Sahin U, Ekici A, Duru S, Ulasli SS, Kurtipek E, Gunay S., RIMPACT Study Investigators. Immunization status in chronic obstructive pulmonary disease: A multicenter study from Turkey. Ann Thorac Med. 2019 Jan-Mar;14(1):75-82. [PMC free article] [PubMed]
Kobayashi M, Farrar JL, Gierke R, Leidner AJ, Campos-Outcalt D, Morgan RL, Long SS, Poehling KA, Cohen AL., ACIP Pneumococcal Vaccines Work Group. CDC Contributors. Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022 Sep 16;71(37):1174-1181. [PubMed]
Dreyzin A, McCormick M, Zullo J, Shah SS, Kalpatthi R. Impact of PCV-13 vaccine on invasive pneumococcal disease in hospitalised children: A multi-institutional analysis. Acta Paediatr. 2021 Feb;110(2):624-630. [PubMed]
Stacey HL, Rosen J, Peterson JT, Williams-Diaz A, Gakhar V, Sterling TM, Acosta CJ, Nolan KM, Li J, Pedley A, Benner P, Abeygunawardana C, Kosinski M, Smith WJ, Pujar H, Musey LK. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults. Hum Vaccin Immunother. 2019;15(3):530-539. [PMC free article] [PubMed]
Essink B, Sabharwal C, Cannon K, Frenck R, Lal H, Xu X, Sundaraiyer V, Peng Y, Moyer L, Pride MW, Scully IL, Jansen KU, Gruber WC, Scott DA, Watson W. Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years. Clin Infect Dis. 2022 Aug 31;75(3):390-398. [PMC free article] [PubMed]
Falkenhorst G, Remschmidt C, Harder T, Hummers-Pradier E, Wichmann O, Bogdan C. Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis. PLoS One. 2017;12(1):e0169368. [PMC free article] [PubMed]
Asai N, Mikamo H. Recent Topics of Pneumococcal Vaccination: Indication of Pneumococcal Vaccine for Individuals at a Risk of Pneumococcal Disease in Adults. Microorganisms. 2021 Nov 12;9(11) [PMC free article] [PubMed]
Siemieniuk RA, Gregson DB, Gill MJ. The persisting burden of invasive pneumococcal disease in HIV patients: an observational cohort study. BMC Infect Dis. 2011 Nov 11;11:314. [PMC free article] [PubMed]
Eichler N, Joseph L, Megged O, Goldberg S, Picard E. The impact of pneumococcal conjugate vaccine on the prevalence and severity of hospitalizations for pneumonia in children. Eur J Clin Microbiol Infect Dis. 2022 Mar;41(3):439-444. [PubMed]
Kobayashi M, Farrar JL, Gierke R, Britton A, Childs L, Leidner AJ, Campos-Outcalt D, Morgan RL, Long SS, Talbot HK, Poehling KA, Pilishvili T. Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):109-117. [PMC free article] [PubMed]
Klein NP, Peyrani P, Yacisin K, Caldwell N, Xu X, Scully IL, Scott DA, Jansen KU, Gruber WC, Watson W. A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age. Vaccine. 2021 Sep 07;39(38):5428-5435. [PubMed]
Cannon K, Elder C, Young M, Scott DA, Scully IL, Baugher G, Peng Y, Jansen KU, Gruber WC, Watson W. A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccination. Vaccine. 2021 Dec 17;39(51):7494-7502. [PubMed]
Lewnard JA, Hanage WP. Making sense of differences in pneumococcal serotype replacement. Lancet Infect Dis. 2019 Jun;19(6):e213-e220. [PubMed]
Papadatou I, Tzovara I, Licciardi PV. The Role of Serotype-Specific Immunological Memory in Pneumococcal Vaccination: Current Knowledge and Future Prospects. Vaccines (Basel). 2019 Jan 29;7(1) [PMC free article] [PubMed]
Boyce JM, Pittet D., Healthcare Infection Control Practices Advisory Committee. HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Guideline for Hand Hygiene in Health-Care Settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America. MMWR Recomm Rep. 2002 Oct 25;51(RR-16):1-45, quiz CE1-4. [PubMed]
Vadlamudi NK, Parhar K, Altre Malana KL, Kang A, Marra F. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: A systematic review and meta-analysis. Vaccine. 2019 Feb 14;37(8):1021-1029. [PubMed]
Kuronuma K, Takahashi H. Immunogenicity of pneumococcal vaccines in comorbid autoimmune and chronic respiratory diseases. Hum Vaccin Immunother. 2019;15(4):859-862. [PMC free article] [PubMed]
Refbacks
- There are currently no refbacks.